科伦药业：公司罗替高汀贴片获得药品注册批准

Core Viewpoint - Kolun Pharmaceutical has received approval from the National Medical Products Administration for its chemical drug "Rotigotine Transdermal Patch," marking it as the world's first transdermal patch for treating Parkinson's disease [1] Group 1: Product Approval - The "Rotigotine Transdermal Patch" is approved for the treatment of early idiopathic Parkinson's disease symptoms and can be used alone or in combination with Levodopa at various stages of the disease [1] - This product is the first domestic generic version approved, enhancing the company's competitiveness in the central nervous system field [1] Group 2: Market Potential - The patch is widely recommended in domestic and international guidelines and expert consensus [1] - Projected global sales for the "Rotigotine Transdermal Patch" are estimated at $330 million in 2024 [1]